25N-NBOMe, also known as 2C-N-NBOMe or NBOMe-2C-N, is a derivative of the hallucinogen 2C-N. The pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but it is believed to act in a similar manner to related compounds such as 25I-NBOMe and 25C-NBOMe, which are potent agonists at the 5HT_2A receptor. 25N-NBOMe has been sold as a street drug and has only been described in the literature in terms of identification by forensic analysis.

The dose range of 25N-NBOMe has been given as 0.1 to 1.3 mg or more sublingually, with a typical dose estimate of 0.6 mg. Whereas 2C-N is much less potent in terms of dose than other 2C drugs, 25N-NBOMe appears to have a similar dose range as other NBOMe drugs.

NBOMe compounds are often associated with life-threatening toxicity and death. Studies on NBOMe family of compounds demonstrated that the substance exhibit neurotoxic and cardiotoxic activity. Reports of autonomic dysfunction remains prevalent with NBOMe compounds, with most individuals experiencing sympathomimetic toxicity such as vasoconstriction, hypertension and tachycardia in addition to hallucinations. Other symptoms of toxidrome include agitation or aggression, seizure, hyperthermia, diaphoresis, hypertonia, rhabdomyolysis, and death. Researchers report that NBOMe intoxication frequently display signs of serotonin syndrome. The likelihood of seizure is higher in NBOMes compared to other psychedelics.

NBOMe and NBOHs are regularly sold as LSD in blotter papers, which have a bitter taste and different safety profiles. Despite high potency, recreational doses of LSD have only produced low incidents of acute toxicity. Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD, and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently". While most fatalities are due to the physical effects of the drug, there have also been reports of death due to self-harm and suicide under the influence of the substance.

Many of the NBOMe compounds have high potency agonist activity at additional 5-HT receptors and prolonged activation of 5-HT_2B can cause cardiac valvulopathy in high doses and chronic use. 5-HT_2B receptors have been strongly implicated in causing drug-induced valvular heart disease. The high affinity of NBOMe compounds for adrenergic α₁ receptor has been reported to contribute to the stimulant-type cardiovascular effects.

In vitro studies, 25C-NBOMe has been shown to exhibit cytotoxicity on neuronal cell lines SH-SY5Y, PC12, and SN471, and the compound was more potent than methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of MAPK/ERK cascade and inhibition of Akt/PKB signaling pathway. 25C-NBOMe, including the other derivative 25D-NBOMe, reduced the visibility of cardiomyocytes H9c2 cells, and both substances downregulated expression level of p21 (CDC24/RAC)-activated kinase 1 (PAK1), an enzyme with documented cardiac protective effects.

25N-NBOMe is a selective and highly potent agonist of the serotonin 5-HT₂ receptors. Its affinities (K_i) are 0.144 nM at the serotonin 5-HT_2A receptor, 8.7 nM at the serotonin 5-HT_2B receptor, and 1.06 nM at the serotonin 5-HT_2C receptor. In terms of affinity, the drug has approximately 7.4-fold selectivity for the serotonin 5-HT_2A receptor over the serotonin 5-HT_2C receptor and 60-fold selectivity for the 5-HT_2A receptor over the serotonin 5-HT_2B receptor.

The EC₅₀Tooltip half-maximal effective concentration (E_maxTooltip maximal efficacy) values of 25N-NBOMe are 0.51 nM (87.9%) at the serotonin 5-HT_2A receptor, 47 nM (57.6%) at the serotonin 5-HT_2B receptor, and 1.32 nM (99.4%) at the serotonin 5-HT_2C receptor. Hence, 25N-NBOMe is a full agonist of the serotonin 5-HT_2A and 5-HT_2C receptors and a partial agonist of the serotonin 5-HT_2B receptor. In terms of functional activity, 25N-NBOMe had 2.6-fold selectivity for the serotonin 5-HT_2A receptor over the serotonin 5-HT_2C receptor and 92-fold selectivity for the serotonin 5-HT_2A receptor over the serotonin 5-HT_2C receptor.